JAK Inhibitors Demonstrate Improved Efficacy Among Various Skin Conditions

Key Takeaways:

• In an analysis of 68 studies, Janus kinase (JAK) demonstrated improved efficacy for skin conditions such as atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa.
• Patients treated with JAK inhibitors had higher response rates than patients who received a placebo.
• JAK inhibitors demonstrated similar safety profiles between drugs, with only a slight increase in toxicity compared to placebo.

Although JAK inhibitors are increasingly being approved by the US Food and Drug Administration (FDA) to treat skin conditions, their long-term efficacy and safety is largely unknown. To address this gap, researchers conducted a systematic review of randomized controlled trials, open-label extensions, and real-world cohort studies published through May 2025 to observe the effectiveness of JAK inhibitors in treating various skin conditions.

Study Methods and Outcomes

The study evaluated 68 studies (42 randomized controlled trials, 14 open-label extensions, and 12 real-world cohorts) containing 15 427 patients with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa.

The main outcomes included Eczema Area and Severity Index (EASI), Psoriasis Area and Severity Index (PASI), Severity of Alopecia Tool (SALT), Vitiligo Area Scoring Index (VASI), and Hidradenitis Suppurativa Clinical Response (HiSCR).

The Impact of JAK Inhibitors on Skin Diseases

When compared with placebo, oral JAK inhibitors demonstrated improved efficacy across various skin conditions.

Patients with atopic dermatitis had EASI-75 rates ranging from 38% to 73%. Patients with Psoriasis had PASI-75 rates between 33% and 67%. Patients with alopecia areata had SALT-50 rates between 30% and 62%.

Topical JAK inhibitors were also effective in treating atopic dermatitis and vitiligo but had limited clinical benefit among patients with alopecia areata.

Toxicity was similar across JAK inhibitors, with low rates of serious adverse events. Patients with JAK inhibitors were more likely to experience upper respiratory infections and herpes zoster reactivation than those with placebo.

The authors said, “JAK inhibitors demonstrate significant efficacy across several inflammatory skin diseases, with a safety profile that warrants ongoing monitoring, particularly in patients with cardiovascular risk factors.”

Reference

Zayed NF, Seetan K, Khamees A, Yassin RY, SA Bashammakh. JAK inhibitors in inflammatory skin diseases: a 15,427-patient systematic review and meta-analysis of clinical trial and real-world outcomes. Clin Drug Invest. 2026. doi:10.1007/s40261-026-01583-7